Viveve Reports Preliminary Full Year 2018 Financial Results

Life Science Investing News

Viveve Medical (NASDAQ:VIVE), a medical technology company focused on women’s intimate health, today reported preliminary financial results for the full year ended December 31, 2018 and provided revenue guidance for 2019. As quoted in the press release: Estimated total revenue from the sale of 57 Viveve Systems worldwide, approximately 4,600 disposable treatment tips and other …

Viveve Medical (NASDAQ:VIVE), a medical technology company focused on women’s intimate health, today reported preliminary financial results for the full year ended December 31, 2018 and provided revenue guidance for 2019.

As quoted in the press release:

Estimated total revenue from the sale of 57 Viveve Systems worldwide, approximately 4,600 disposable treatment tips and other ancillary consumables during the three months ended December 31, 2018, is expected to be approximately $4.4 million. Estimated total revenue for the full year 2018 is expected to be approximately $18.5 million from the sale of 259 Viveve Systems worldwide (203 in North America) and approximately 18,450 disposable treatment tips and other ancillary consumables, compared to revenue of $15.3 million for the full year 2017.  This is an increase of $3.2 million or 21% year-over-year.

Cash and cash equivalents were approximately $29.5 million as of December 31, 2018, an increase of $8.8 million from $20.7 million as of December 31, 2017.

Viveve’s 2018 fourth quarter and year-end anticipated revenue results are preliminary and based on the most current information available and are subject to completion of the consolidated financial statements. The company plans to report its final fourth quarter and year-end 2018 financial results in March 2019.

Click here to read the full press release.

The Conversation (0)
×